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BACKGROUND: Identifying beneﬁcial surrogate genetic markers in psychiatric disorders is crucial but challenging.
METHODS: Given that scalp hair follicles are easily accessible and, like the brain, are derived from the ectoderm,
expressions of messenger RNA (mRNA) and microRNA in the organ were examined between schizophrenia (n for
ﬁrst/second 5 52/42) and control subjects (n 5 62/55) in two sets of cohort. Genes of signiﬁcance were also
analyzed using postmortem brains (n for case/control 5 35/35 in Brodmann area 46, 20/20 in cornu ammonis 1) and
induced pluripotent stem cells (n 5 4/4) and pluripotent stem cell-derived neurospheres (n 5 12/12) to see their role
in the central nervous system. Expression levels of mRNA for autism (n for case/control 5 18/24) were also examined
using scalp hair follicles.
RESULTS: Among mRNA examined, FABP4 was downregulated in schizophrenia subjects by two independent
sample sets. Receiver operating characteristic curve analysis determined that the sensitivity and speciﬁcity were
71.8% and 66.7%, respectively. FABP4 was expressed from the stage of neurosphere. Additionally, microarray-
based microRNA analysis showed a trend of increased expression of hsa-miR-4449 (p 5 .0634) in hair follicles from
schizophrenia. hsa-miR-4449 expression was increased in Brodmann area 46 from schizophrenia (p 5 .0007). Finally,
we tested the expression of nine putative autism candidate genes in hair follicles and found decreased CNTNAP2
expression in the autism cohort.
CONCLUSIONS: Scalp hair follicles could be a beneﬁcial genetic biomarker resource for brain diseases, and further
studies of FABP4 are merited in schizophrenia pathogenesis.
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Biohttp://dx.doi.org/10.1016/j.biopsych.2014.07.025The disease mechanisms underlying psychiatric illnesses
remain largely undetermined. Great efforts have gone into
identifying novel biomarkers that would assist in the develop-
ment of objective diagnostic tools and novel therapeutic and
prophylactic interventions, as well as facilitate the subdivi-
sion of disease states, based on pathogenesis, for optimal
drug selection. There are, however, major obstacles in the
search for novel biomarkers, primarily the difﬁculty in obtain-
ing brain tissue from living donors and the lack of accurate
experimental animal models. Brain is an ectodermal tissue
and shares its developmental origins with scalp hair follicles,
which are readily accessible miniorgans within the skin.
Despite their shared embryonic origins, hair follicles have
not previously been utilized as a bio-resource in the hunt for
proxy genes in psychiatric diseases. In the current study, we
ﬁrst examined whether schizophrenia-relevant genes, namely
those related to the γ-aminobutyric acid (GABA)ergic system
(1–3), myelin (3–5), and fatty acids (6–11), are expressed in6 & 2015 Society of Biological Psychiatry
logical Psychiatry July 15, 2015; 78:116–125 www.sobp.org/journal
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Open access under CC BY-NC-ND lhair follicles and if expressed whether expression is differ-
ential between cases and control subjects, using an explor-
atory sample set. Next, we attempted to validate any
differential expression and examine the effects of potential
confounding factors using a second independent sample set.
We then analyzed the identiﬁed biomarker candidate FABP4/
fatty acid binding protein 4 (FABP4) expression in serum,
postmortem brain samples, induced pluripotent stem cells
(iPSCs), and iPSC-derived neurospheres. In addition to
messenger RNA (mRNA), we also examined the expression
levels of microRNA (miRNA) in hair follicles, postmortem
brains, iPSCs, and iPSC-derived neurosphere samples from
patients with schizophrenia and control subjects. Lastly, we
tested candidate gene expression in hair follicles from
patients with autism. Based on the results of our compre-
hensive analysis, we proposed scalp hair follicles as a
beneﬁcial genetic resource for schizophrenia and autism in
the search for potential biomarkers.ISSN: 0006-3223
RY ON PAGE
icense.
Scalp Hair Follicles as Disease Biomarkers
Biological
PsychiatryMETHODS AND MATERIALS
Scalp Hair Follicle Samples
All samples were collected from ethnic Japanese within Japan.
The ﬁrst set of exploratory scalp hair follicle samples for
schizophrenia and control subjects was derived from residents
in the northern district of Kanto, while the conﬁrmatory second
set came from the Tokyo area. Diagnoses were made by at
least two experienced psychiatrists, using DSM-IV criteria.
Demographic data for scalp hair follicle samples derived from
schizophrenia are described in Table 1. The scalp hair follicle
samples from autism participants and control subjects were
collected from the Chubu area. The diagnosis of autism
spectrum disorder was made using the DSM-IV-TR criteria.
We then administered the Autism Diagnostic Interview-
Revised (ADI-R) (12) to 14 of 18 cases and made a conﬁrmed
diagnosis of autism for those 14 cases. Interviews for the ADI-
R were conducted by experienced child psychiatrists who are
licensed to use the Japanese version of the ADI-R (13).
Demographic data relating to scalp hair follicle samples for
autism are described in Table 1.
RNA Extraction and Quantiﬁcation
Ten hairs were plucked from the scalp of each subject using
forceps. The hairs were checked for the presence of a sheath.
Hairs were trimmed to approximately 1.5 cm in length,
containing the bulb region, and dropped into a 1.5 mL micro-
fuge tube (BM Equipment, Tokyo, Japan) containing RNAlater
solution (Ambion, Grand Island, New York). Total RNA was
extracted using the RNAqueous-Micro kit (Ambion). Single-
stranded complementary DNA (cDNA) was synthesized using
SuperScript VILO Master Mix (Invitrogen, Grand Island, New
York). Quantitative reverse-transcription PCR (qRT-PCR) anal-
ysis of mRNAs was conducted using an ABI7900HT Fast Real-
Time PCR System (Applied Biosystems, Grand Island, New
York). TaqMan probes were TaqMan Gene Expression Assays
products (Applied Biosystems). All qRT-PCR data were cap-
tured using the SDS v2.4 (Applied Biosystems). The ratios of
relative concentrations of target molecules to the GAPDHTable 1. Demographic Characteristics of Hair Follicle Sample S
Control Subject
First Sample Set for Schizophrenia
n 62
Sex (female/male) 41 / 21
Age (mean 6 SD) 41.26 6 12.26
Second Sample Set for Schizophrenia
n 55
Sex (female/male) 26 / 29
Age (mean 6 SD) 46.87 6 13.56
Duration of illness (mean 6 SD)
Autism Sample Set
n 24
Sex (female/male) 24 / 0
Age (mean 6 SD) 32.60 6 3.91
aEvaluated by chi-square test.
bEvaluated by two-tailed t test.
Biologicalgene (target molecule/GAPDH gene) were calculated. All
reactions were performed in triplicate based on the standard
curve method.
Statistical Analysis
We used the interquartile range to ﬁnd outliers. The differences
between the 25th (quartile 1) and 75th percentiles (quartile 3)
were used to identify extreme values (outliers) in the tails of the
distribution. Statistical evaluation was performed by Mann-
Whitney U test for means between patient and control groups
and by Spearman's R test for correlation using SPSS software
version 19 (IBM, Tokyo, Japan).
Analyses of miRNA Expressions and Potential
Targets of miRNAs
For microarray-based miRNA analysis, we used the miRBase
Rel. 18.0 platform (Agilent Technologies, Santa Clara Califor-
nia), capable of measuring 1919 human mature miRNAs in the
age-/sex-matched subset of the ﬁrst hair follicle sample set
(Table S1 in Supplement 1). The miRNAs were labeled using
the miRNA Complete Labeling Reagent and Hyb Kit (Agilent
Technologies) and hybridized to the arrays. Images were
scanned with a High-Resolution C scanner (Agilent Technol-
ogies) and analyzed using GeneSpring GX (Agilent Technolo-
gies). Comparisons of miRNA expression values between
schizophrenia and control groups were performed using
GeneSpring 12.6 (Agilent Technologies). To normalize the
intermicroarray range of expression intensities, the percentile
shift method (90th percentile) was used. The genes whose
expression data were available in more than 50% of hybrid-
izations were statistically evaluated between schizophrenia
and control groups using the two-tailed Mann-Whitney
U test. For quantiﬁcation of individual miRNAs, we performed
TaqMan-based miRNA qRT-PCR (Applied Biosystems, Grand
Island, New York) according to the manufacturer’s instruc-
tions, using U6 snRNA as a control probe. All reactions for
miRNA quantiﬁcation were also performed in triplicate, based
on the standard curve method. Statistical evaluation methods
were the same as those for mRNA.ets
s Patients p Value
52
25 / 27 .0518a
50.98 6 10.86 ,.0001b
42
20 / 22 .973a
49.93 6 12.97 .2777b
22.79 6 14.66
18
16 / 2 .1777a
25.61 6 4.95 ,.0001b
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PsychiatryTo identify the potential targets of a speciﬁc miRNA, we
performed in silico analysis using web-based miRNA target
prediction methods, TargetScan (http://www.targetscan.org,
Release 6.2; Whitehead Institute for Biomedical Research,
Cambridge, Massachusetts) and miRDB (http://mirdb.org/
miRDB/; Washington University School of Medicine, St. Louis,
Missouri).
Immunohistochemistry
The plucked hairs were rinsed brieﬂy in phosphate-buffered
saline and dropped into a 1.5 mL microfuge tube containing 1
mL of 10% neutral-buffered formalin (41C, 1 hour). The ﬁxed
hairs were pre-embedded in 4% agarose (Sigma-Aldrich, St
Louis, Missouri) in phosphate-buffered saline, pH 7.4. At this
point, it was possible to orientate the hairs into their desired
position for either longitudinal or transverse sectioning. Blocks
were embedded in capsules, which were ﬁlled with O.C.T.
compound (Sakura Finetek, Tokyo, Japan). Cryostat sections
(8 μm thick) of plucked hair follicles were processed for immuno-
histochemistry. The sections were blocked with 10% goat serum
in .05 mol/L Tris buffered saline plus .05% Tween 20 (TBST),
followed by three rinses in TBST (20 min each). The primary
antibodies were applied for overnight at 41C. After three washes
in TBST (20 min each), secondary antibodies were applied to
sections at room temperature (1 hour). Slides were counterstained
with 4’,6-diamidino-2-phenylindole to highlight nuclei. After wash-
ing in TBST, the slides were mounted in PermaFluor Aqueous
Mounting Medium (Thermo Fisher Scientiﬁc, Waltham, Massa-
chusetts). Fluorescent signals were detected using a confocal
laser-scanning microscope FV1000 (Olympus, Tokyo, Japan).
Antibodies
See Supplementary Methods and Materials in Supplement 1.
Analysis of FABP4 Protein Levels in Serum
See Supplementary Methods and Materials in Supplement 1.
Postmortem Brain Analysis
See Supplementary Methods and Materials in Supplement 1.
Establishment of iPSC Lines
Dermal ﬁbroblasts (human dermal ﬁbroblasts) from the facial
dermis of a 36-year-old Caucasian female subject (Cell Applica-
tions, Inc., San Diego, California) were used to establish control
iPSCs 201B7 and YA9 (14). The remaining control iPSCs, WD39
and KA23, were generated from a 16-year-old Japanese female
subject (15) and a 40-year-old Japanese male subject (Matsumoto,
Ph.D., et al., personal communication, 2013), respectively. The
201B7 iPSCs were kindly provided by Yamanaka, M.D., Ph.D.,
Kyoto University (14). The iPSCs YA9, WD39, and KA23 have been
described in a previous report (15). The schizophrenia derived
iPSCs from patients with 22q11.2 deletions SA001 and KO001
were generated from Japanese female subjects aged 37 and 30
years old, respectively (see Clinical History in Supplement 1).
The maintenance of human dermal ﬁbroblasts, lentiviral pro-
duction, retroviral production, infection, stem cell culture, and
characterization were performed as described previously (15).118 Biological Psychiatry July 15, 2015; 78:116–125 www.sobp.org/joIn Vitro Neural Differentiation of Induced Pluripotent
Stem Cells
The iPSCs were plated in T75 ﬂasks after dissociation into
single cells and cultured for 14 days in neural culture medium
supplemented with leukemia inhibitory factor (Merck Millipore,
Darmstadt, Germany) and basic ﬁbroblast growth factor
(Peprotech, Rocky Hill, New Jersey). Neurospheres were
passaged repeatedly by culturing in the same manner (16,17).
Comparative Genomic Hybridization Array Analysis
See Supplementary Methods and Materials in Supplement 1.
Ethical Issues
This study was approved by the Ethics Committees of RIKEN
and all participating institutes, including the Keio University
School of Medicine, an ethical committee for skin biopsy and
iPSC production (approval No. 20080016), and conducted
according to the principles expressed in the Declaration of
Helsinki. All control subjects and patients gave informed, written
consent to participate in the study after being provided with and
receiving an explanation of study protocols and objectives.RESULTS
Expression of mRNA in Scalp Hair Follicles from
Schizophrenia and Control Subjects
Gene expression proﬁles of schizophrenia postmortem brains
have been well studied. However, studies have been hampered
by uncontrollable confounding factors associated with postmor-
tem brains and an inaccessibility of brain tissue from living
donors. Therefore, we set out to analyze gene expression in hair
follicles. Previous studies provide substantial support for reduced
expression of genes related to oligodendrocyte and GABAergic
systems in schizophrenia pathology (1–4). In addition, our (6,7,9)
and other studies (8,10,11) on FABPs (genes for fatty acid
binding proteins) raise the possibility of disturbed lipid metabo-
lism in the susceptibility to this disease. Based on these ﬁndings,
we selected 22 genes: 8 from the GABAergic system, 9 with
myelin relevance, and 5 with lipid relevance (Table 2). The
amount of mRNA from an individual subject’s hair follicles was
not enough for a systemic cDNA microarray. We used GAPDH
as an internal control. An exploratory scalp hair follicle sample
panel (the ﬁrst sample set) consisted of samples from 52 patients
with schizophrenia and 62 control subjects (Table 1). qRT-PCR
analysis showed that seven genes, namely CALB2, SST, CNP,
PMP22, FABP4, FABP7, and FAAH were differentially expressed
(p , .05) in samples from schizophrenia compared with control
subjects (Table 2; Figure S1 in Supplement 1).
To replicate the ﬁnding, we examined the expression levels
of these seven genes using an age-/sex-matched, independ-
ent conﬁrmatory set (a second sample set) composed of 42
patients with schizophrenia and 55 control subjects (Table 1).
Of the seven genes, only FABP4 showed signiﬁcantly dec-
reased expression (an average reduction of 43% compared
with a reduction of 40% in the ﬁrst set of samples) in
schizophrenia samples (Figure 1A; Table 2). Correlation anal-
yses demonstrated no signiﬁcant effects for age, dose ofurnal
Table 2. List of Examined Genes and Their Expression in the First and Second Scalp Hair Follicle Sample Sets from
Schizophrenia
Gene Category Gene Symbol Assay IDa
First Sample Set Second Sample Set
Mean 6 SD of Corresponding
Gene / GAPDH
Mean 6 SD of Corresponding
Gene / GAPDH
Control
(n 5 62)
Schizophrenia
(n 5 49) p Valueb
Control
(n 5 62)
Schizophrenia
(n 5 49) p Valueb
GABAergic System GAD1 Hs01065893_m1 .881 6 .598 1.119 6 .707 .118
GAD2 Hs00609534_m1 Not detectable
GABRA1 Hs00168058_m1 2.347 6 2.761 .832 6 .964 .378
GABRD Hs00181309_m1 1.055 6 .758 .945 6 .618 .666
SLC6A1 Hs01104475_m1 1.047 6 .830 .985 6 .555 .682
PVALB Hs00161045_m1 1.067 6 .569 1.074 6 .669 .87
CALB2 Hs00418693_m1 1.024 6 .355 1.163 6 .303 .037d .715 6 .373 .857 6 .300 .095c
SST Hs00356144_m1 .626 6 .549 1.052 6 .923 .028d .910 6 .683 1.812 6 1.802 .151c
Myelin Relevance APC Hs01568269_m1 1.001 6 .243 .939 6 .233 .131
CLDN11 Hs00194440_m1 .860 6 .605 .984 6 .854 .862
CNP Hs00263981_m1 1.148 6 .336 .985 6 .186 .002d .928 6 .415 1.052 6 .210 .456
CSPG4 Hs00361541_g1 .976 6 .536 1.050 6 .364 .252
MAG Hs01114387_m1 Not detectable
NES Hs00707120_s1 1.018 6 .496 1.013 6 .403 .98
OLG2 Hs00300164_s1 Not detectable
PMP22 Hs00165556_m1 1.006 6 .370 .804 6 .261 .003d .807 6 .410 .844 6 .400 .987
SOX10 Hs00366918_m1 1.072 6 .748 .984 6 .508 .99
Lipid Relevance FABP3 Hs00997360_m1 .763 6 .486 .807 6 .372 .292
FABP4 Hs01086177_m1 1.050 6 .470 .653 6 .251 ,.0001d 1.138 6 .708 .650 6 .232 ,.001
FABP5 Hs02339439_g1 1.118 6 .215 1.084 6 .179 .312
FABP7 Hs00361426_m1 .562 6 .332 1.018 6 .744 .003d .519 6 .372 .530 6 .355 .754
FAAH Hs01038660_m1 1.008 6 .344 .857 6 .221 .013d .836 6 .303 .753 6 .281 .180c
Control GAPDH Hs02758991_g1
GABA, gamma-aminobutyric acid.
aProbe ID in TaqMan Gene Expression Assay system.
bEvaluated by two-tailed Mann-Whitney U test.
cFor these analyses, only 49 control and 36 schizophrenia samples were available.
dSigniﬁcant changes.
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Psychiatryantipsychotics [haloperidol equivalent (18,19)], or duration of
illness on the expression levels of FABP4 (Figure S2A–C in
Supplement 1). Since serum levels of Fabp4 were reported to
be affected by nutritional ﬂuctuations in mice (that is, sup-
pressed by feeding) (20), we examined the effect of sampling
time after the last meal on FABP4 expression in hair follicles
and found no signiﬁcant change (Figure S2D in Supplement 1).
Nor did we detect an effect for sex on FABP4 levels: male
control versus female control subjects, p 5 .950; male schizo-
phrenia versus female schizophrenia subjects, p 5 .360; male
(control 1 schizophrenia subjects) versus female (control 1
schizophrenia subjects), p 5 .387; all evaluated by the Mann-
Whitney U test.
Circulating FABP4 is known to be associated with meta-
bolic markers (21,22), so we examined the effects of weight,
height, body mass index, and body fat percentage on FABP4
expression in the second hair follicle sample set (Figure S3 in
Supplement 1). None of these factors affected the expression
ratios of FABP4/GAPDH in hair follicles. Despite the fact that
olanzapine alters lipid metabolism (23,24), we detected no
signiﬁcant correlation between FABP4 expression levels in hair
follicles and olanzapine dose (mg/day) in the second set of
schizophrenia samples (Spearman’s rho = 2.2289; 95%
conﬁdence interval = 2.5258 to .1178; p = .180).
From these results, FABP4 expression levels in hair follicles
would appear to be a robust marker for schizophrenia.
Receiver operating characteristic curve analysis determined
an optimal cutoff level of .769, based on the minimum distanceBiologicalfrom the curve to upper left corner (= .191) and area under the
curve = .713 (95% conﬁdence interval = .609–.817) (Figure S4
in Supplement 1). With this cutoff level for the FABP4/GAPDH
mRNA ratio, the sensitivity, speciﬁcity, and positive and
negative predictive values were 71.8%, 66.7%, 60.9%, and
76.6%, respectively.
Immunohistochemical Analysis of FABP4 in Scalp
Hair Follicles
Figure 2A shows the structure of a hair follicle (25,26). Moving
inward, a plucked scalp hair consists of the following compo-
nents: the outer root sheath, companion layer, inner root sheath
(IRS), the cortex, and medullar. Each of these components has
an epidermal origin and each compartment expresses speciﬁc
genes from the keratin family (26) (Figure 2B). FABP4 is co-
expressed with K71 in the IRS cuticle layer and displays
partially overlapping expression with K85 in the cuticle,
matrix/precortex, and mid/upper cortex (27). However, FABP4
shows scant co-expression with K14 in the outer root sheath
layer (Figure 2C, D). These results indicate that FABP4 is
expressed in the IRS and part of the hair cortex.
Expression of FABP4 in Serum and Postmortem
Brains
We measured FABP4 protein levels in the same cohort as the
second hair follicle sample, using an enzyme-linked immuno-
sorbent assay kit, to see whether serum levels of FABP4 couldPsychiatry July 15, 2015; 78:116–125 www.sobp.org/journal 119
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Figure 1. FABP4/fatty acid binding protein 4 (FABP4) expression analyses in schizophrenia and control samples. (A, B, D, E) Results for hair follicles (the
second sample set), serum, and postmortem brain tissue (Brodmann area [BA]46 and cornu ammonis [CA]1) are shown. GAPDH was used as an internal
control. p values were calculated using two-tailed Mann-Whitney U test. Horizontal bars show mean 6 SD. (C) Correlations between relative FABP4 expression
levels in scalp hair follicles and FABP4 levels in serum are also shown. Statistical evaluations were performed using Spearman’s rank correlation test.
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not differ signiﬁcantly between schizophrenia and control
samples, although a trend of increase was seen in schizo-
phrenia (Figure 1B). In addition, using the second sample
cohort, there was no signiﬁcant correlation between serum
FABP4 and FABP4 mRNA levels in hair follicles (Figure 1C).
Interestingly, in contrast to ﬁndings in mice (20), serum FABP4
levels were not affected by time elapsed after the last meal in
either disease or control groups (Figure S5 in Supplement 1).
In postmortem brains, FABP4 transcript expression was
signiﬁcantly elevated in the frontal cortex (Brodmann area
[BA]46) of schizophrenia compared with control samples
(p 5 .0047) (Figure 1D), suggesting its role in schizophrenia
pathophysiology. Expression of FABP4 in hippocampus cornu
ammonis 1 remained unchanged between schizophrenia and
control samples (Figure 1E), implicating region speciﬁcity for the
function of FABP4 in schizophrenia. Both of these brain regions
showed particularly high expression levels in four schizophrenia
samples derived from patients not recorded to have taken
particular therapeutic drugs (Table S3 in Supplement 1),
although the possibility of drug effects cannot be excluded.
Expression Analysis of miRNAs in Scalp Hair Follicles
and Postmortem Brains
We further performed microarray-based miRNA analysis and
measured the expression levels of 1919 human mature
miRNAs using the miRBase Release 18.0 platform (Agilent)
in an age- and sex-matched subset of the ﬁrst hair follicle120 Biological Psychiatry July 15, 2015; 78:116–125 www.sobp.org/josample set (Table S1 in Supplement 1). We detected three
miRNAs, which satisﬁed our criteria of an absolute fold change
(FC) (schizophrenia group/control group) $ 2 and p , .05
(by Mann-Whitney U test, two-tailed). These were hsa-miR-
4449 (FC 5 3.45, p 5 .0032), hsa-miR-1237 (FC 5 2.55,
p 5 .028), and hsa-miR-4769-3p (FC 5 2.03, p 5 .028). In the
next step, we tested these three miRNAs in the second hair
follicle sample set (Table 1), using qRT-PCR, with U6 small
nuclear RNA as a control probe. hsa-miR-4449 showed a top
hit with upregulation, although not to signiﬁcant levels, in
schizophrenia (FC 5 1.25, p 5 .063) (Figure 3A).
In postmortem brains (BA46), hsa-miR-4449 showed
increased expression (p 5 .0007) in schizophrenia samples
(Figure 3B), suggesting possible contribution of this gene also
to schizophrenia.
Expression Analysis of FABP4 and hsa-miR-4449 in
iPSCs and iPSC-Derived Neurospheres
Recently, iPSCs have been used for human disease modeling,
particularly in neurological disorders (28–30). We have estab-
lished iPSCs from control subjects (one line each from four
subjects) and schizophrenia patients carrying a 22q11.2
microdeletion (two lines each from two patients) (31)
(Figure 4). Then, we established three neurosphere lines from
each iPSC line. We chose 22q11.2 deletion carriers for
analysis (for comparative genomic hybridization array analysis
using the iPSCs, see Supplementary Methods and Materials in
Supplement 1), since the 22q11.2 deletion is a well-deﬁnedurnal
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Figure 2. Expression patterns of fatty acid binding protein 4 (FABP4) in scalp hair follicles. (A) Schematic illustration showing the structure of hair follicles.
(B) Schematic presentation of epithelial/hair keratin expression patterns. Keratin K71 is expressed in the three inner root sheath (IRS) layers, while K14 is
known as outer root sheath (ORS) keratin. Keratin K85 is present in the hair-forming compartment. (C) Immunoﬂuorescent labeling of FABP4 and hair keratins
(K14, K71, and K85) in scalp hair follicles. K14 is uniformly expressed throughout the widely stratiﬁed follicular ORS. K71 is expressed in all compartments of
the hair IRS. Keratin K85 expression extends from the hair matrix to the upper cortex and the hair cuticle. FABP4 is seen in the IRS and part of the hair cortex
(merged green and red). 4',6-diamidino-2-phenylindole (DAPI) was used for nuclear staining. (D) Magniﬁed picture of (C). APM, arrector pili muscle; cl,
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Figure 3. Expression analyses of hsa-miR-4449 in
schizophrenia and control samples. Results from hair
follicles (the second sample set) (A), postmortem
brains (Brodmann area [BA]46) (B), induced pluripo-
tent stem cells (iPSCs) (C), and neurospheres (D) are
shown. U6 small nuclear RNA (snRNA) was used as
an internal control. p values were calculated using
two-tailed Mann-Whitney U test. Horizontal bars
show mean 6 SD.
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Psychiatrygenetic feature with the highest risk for schizophrenia, affecting
around .3% of schizophrenia patients (32). The FABP4 gene
shows little expression in iPSCs derived from either control
subjects or patients (data not shown). The gene is expressed in
neurospheres, suggesting that its expression starts at a very
early stage of neuronal development. Neurospheres are com-
posed of free-ﬂoating clusters of neural stem or progenitor
cells, differentiated from iPSCs. However, FABP4 expression
levels were not signiﬁcantly different between control subjects
and cases (Figure S6 in Supplement 1; expressional variance in
the control group was large). Expression of hsa-miR-4449
showed a trend of upregulation in iPSCs from patients (p 5
.0571) (Figure 3C); however, there was no differential expression
between neurospheres derived from control subjects and cases
(Figure 3D).
Examination of Autism Samples
We also performed a preliminary study to examine whether
expression patterns of putative autism genes in scalp hair
follicles could discriminate between autism and control sam-
ples. The sample cohort is shown in Table 1. We selected
genes from candidates for autism susceptibility and included
FABP4, due to the genetic overlap between schizophrenia and
autism (33). The remaining genes were FABP7 (9), NHE6 (34),
NHE9 (34), A2BP1 (35), CADPS2 (36), AH1 (35), CNTNAP2
(35), and SLC25A12 (35). Of the nine genes, only CADPS2
(p 5 .0401) and CNTNAP2 (p 5 .0212) showed signiﬁcantly
decreased expression in autism-derived samples compared
with control follicles (Figure S7 in Supplement 1). It should be
noted that the average age of autism subjects was signiﬁ-
cantly lower than that of control subjects (Table 1) and that
CADPS2 levels showed a positive correlation with age in
autism and control 1 autism groups (Figure S8 in Supplement 1).122 Biological Psychiatry July 15, 2015; 78:116–125 www.sobp.org/joTherefore, we can only safely nominate CNTNAP2 level as a
potentially valid marker for autism in this study (Figure S9 in
Supplement 1). Approximately half of the examined patients
were medicated. However, these patients were not outliers in
terms of CNTNAP2 expression in hair follicles; that is, they fell
within the mean 6 2SD (detailed data not shown).DISCUSSION
We examined and attempted to validate expression levels of
schizophrenia and autism candidate genes using scalp hair
follicles as a surrogate source of disease markers. Of the
protein-coding genes tested that are putative schizophrenia
genes, FABP4 was conﬁrmed to be downregulated in disease
samples in our two-stage analyses. Our low rate of replication
could be due to two main factors. First, the current sample
size is insufﬁcient, which may represent one of the limitations
in this study. Another potential reason might be that stable
detection of expression levels is dependent on where a
particular gene is expressed in the hair follicle. For instance,
FABP4 is expressed in more central portions (IRS and cortex)
of the hair follicle and the integrity of these areas may be well
maintained during the plucking process, leading to more
consistent results.
FABP4, also known as adipocyte-speciﬁc fatty acid-binding
protein, belongs to the fatty acid-binding protein super family,
whose members have molecular masses of approximately
15,000. FABPs are highly conserved cytoplasmic proteins that
bind long-chain fatty acids and other hydrophobic ligands. It is
thought that FABPs are active in fatty acid uptake, transport,
and metabolism. In the periphery, FABP4 is highly expressed
in adipose tissue and moderately expressed in macrophages,
endothelial cells, and bone marrow (37). The protein has been
intensively studied in terms of systemic insulin sensitivity andurnal
Figure 4. Establishment of iPSCs
and iPSC-derived neurospheres
from controls and schizophrenia
patients with a 22q11.2 deletion
(also see ref. 31). (A) Demographic
data and I.D. information for samples
are shown. (B) CGH array analysis of
chromosome 22 using iPSCs
showed that all the iPSC lines
derived from the patients carried a
2.6 Mb hemizygous deletion at chro-
mosome 22q11.2. (C) Alkaline phos-
phatase (AP) staining of iPSCs from
controls (WD39, 201B7, YA9 and
KA23). AP activity was detected
using an Alkaline Phosphatase
Staining kit (Miltenyi Biotec, Bergisch
Gladbach, Germany). (D) Those from
patients with a 22q11.2 deletion
(SA001-1D2, SA001-3B1, KO001-19
and KO001-25). All the iPSC clones
were AP-positive showing the plur-
ipotency. Scale bars: phase contrast
and AP staining, 400 μm; neuro-
spheres, 150 μm. iPSC, induced
pluripotent stem cells.
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Psychiatrylipid and glucose metabolism, both of which correlate with
inﬂammatory mechanisms (21). Since the results showing
downregulation of FABP4 in scalp hair follicles from schizo-
phrenia subjects are robust against confounding factors,
including those related to metabolic state, our ﬁndings are
unlikely to represent either metabolic or inﬂammatory con-
ditions. In addition, our patients had been treated with second-
generation antipsychotics, including olanzapine, which often
induce metabolic syndrome, but FABP4 levels in hair follicles
were independent of drug dose and duration of illness.
Conformingly, there was no signiﬁcant correlation between
serum FABP4 and FABP4 transcript levels in hair follicles.
Therefore, elevated FABP4 expression in hair follicles may
point toward a pathophysiological step in schizophrenia.
In our protocol, all cells in neurospheres expressed the neural
markers Nestin, or β3-tubulin, suggesting that our neurospheres
consist almost entirely of neural stem or progenitor cells (38). The
fact that FABP4 is expressed in neurospheres may suggest a
potential role in neuronal stem cell maintenance or neuronal
differentiation or both processes. Although iPSC-derived neuro-
spheres showed no signiﬁcant differences in FABP4 expression
levels between control and schizophrenia cohorts, before a
conclusion can be made, it would be necessary to examine a
much larger cohort. According to the Human Protein Atlas
database (Knut and Alice Wallenberg Foundation, Stockholm,
Sweden; http://www.proteinatlas.org/), FABP4 transcripts areBiologicalexpressed in neuronal cells (35%) and glial and endothelial cells
(65%) of the adult cerebral cortex.
To evaluate whether common genetic variants of FABP4
determine a predisposition to schizophrenia, we performed a
genetic association study using approximately 2000 schizo-
phrenia cases and 2000 age- and sex-matched control
subjects with six tag single nucleotide polymorphisms (Sup-
plementary Methods and Materials in Supplement 1). This
analysis found no signiﬁcant allelic or genotypic association
(Table S4 in Supplement 1). The FABP4 gene is composed of
two haplotype blocks, based on Gabriel's conﬁdence intervals
(39) (Figure S10 in Supplement 1). Haplotype analysis also
failed to reveal any signiﬁcant signals. The exact reasons for
the different directional changes seen in hair follicles, serum,
postmortem brains, and neurospheres between control and
schizophrenia subjects remain unknown. All FABP family
genes contain a canonical TATA box, followed by a conserved
gene structure. The tissue-speciﬁc and developmental regu-
lation of FABP subtype expression, including that of FABP4, is
thought to be controlled by unidentiﬁed genomic regulatory
elements (6,40).
Mechanistically speaking, although not yet conﬁrmed, the
FABP4 may be more central to schizophrenia pathophysiology
beyond being a mere biomarker for disease. This is based on
the following observations: 1) FABP4 is expressed in the early
neuronal lineage (a current ﬁnding); 2) other FABP genes arePsychiatry July 15, 2015; 78:116–125 www.sobp.org/journal 123
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Psychiatryreported to be associated with schizophrenia (6,7,9,11); and
3) there is evidence linking polyunsaturated fatty acids
(endogenous ligands for FABPs) with schizophrenia etiology
(41) and brain development (42).
Regarding miRNA, we detected hsa-miR-4449 from a total of
1919 human mature miRNAs in this study. Although its expres-
sion in hair follicles was not signiﬁcantly altered, expression did
show signiﬁcant upregulation in postmortem brains (BA46) and a
trend of increase in iPSCs from schizophrenia samples. Web-
based target predictions for hsa-miR-4449 hit 18 protein-coding
genes using TargetScan (Whitehead Institute for Biomedical
Research, Release 6.2) (Table S5 in Supplement 1) and 10
protein-coding genes using miRDB (Washington University School
of Medicine; http://mirdb.org/miRDB/) (Table S6 in Supplement 1).
Between the two programs, the following three genes over-
lapped: 1) HIC1; 2) RBM4; and 3) TOMM40. Although the
predicted roles for these three genes in schizophrenia patho-
genesis are not known, hsa-miR-4449 would make an interest-
ing candidate in future studies, since this miRNA is expressed in
early human neurodevelopmental stages such as iPSCs and
iPSC-derived neurospheres.
In the analysis of autism-derived scalp hair follicles, we
found signiﬁcant downregulation of CNTNAP2 in sufferers
compared with control subjects and that the results are not
affected by age. CNTNAP2, which encodes the contactin
associated protein-like 2, is one of the strongest autism
susceptibility genes with convergent evidence from several
independent studies (43).
In the case of schizophrenia, biomarkers are an essential
tool, particularly in the early phase of disease onset, such as
the prodromal phase or at-risk mental state (44). It would be
important to conﬁrm whether FABP4 expression levels in scalp
hair follicles constitute a valid measure for discriminating
between those individuals in at-risk mental state who will
spontaneously recover and those who will need therapeutic
treatment. As a starting point, it is interesting that the
decreased FABP4 levels in schizophrenia-derived hair follicles
are not inﬂuenced by duration of illness.
In summary, our results provide an original concept for
identifying novel disease markers, with potential beneﬁts for
the clinical practice of psychiatric medicine, as well as
possible applications to other brain disorders. The develop-
ment of methods that enable the analysis of a transcriptome
using hair follicles (10 samples) would be highly desirable. At
the moment, approximately 40 ng of total RNA is extractable
from a single hair follicle, but this amount is not enough for
currently available cDNA microarray analysis, a technique
which needs roughly 1 mg of total RNA.ACKNOWLEDGMENTS AND DISCLOSURES
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